Spot Trading’s Emergent Biosolutions EBS Stock Holding History

Spot Trading’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-7,800	Closed	-$219K	–	3161
2016 Q2	$219K	Buy	+7,800	New	+$306K	﹤0.01%	2156

Other funds holding EBS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AAM

Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Spot Trading's EBS Position: Q3 2016 in Review

Spot Trading sold out of Emergent Biosolutions (EBS) in Q3 2016, closing a stake of 7,800 shares — an estimated $219K sold.

Spot Trading first reported a position in EBS in Q2 2016 and held it in 1 quarter. The position peaked at $219K in Q2 2016. 203 funds tracked by Wall St. Rank hold EBS as of Q3 2016.

Spot Trading reported no remaining Emergent Biosolutions position as of Q3 2016 after selling out during the quarter.
Spot Trading sold 7,800 Emergent Biosolutions shares in Q3 2016, an estimated $219K.
Spot Trading first reported a position in Emergent Biosolutions in Q2 2016 and held it in 1 quarter.
Spot Trading's Emergent Biosolutions position peaked at $219K in Q2 2016.
203 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2016.

Based on Spot Trading's 13F filing for Q3 2016, filed 31 Oct 2016.